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ORIGINAL ARTICLE
Infection-Related Hospitalization in Heart Failure 
With Reduced Ejection Fraction
A Prospective Observational Cohort Study
Michael Drozd, MBChB*; Ellis Garland, BSc*; Andrew M.N. Walker, MBChB, PhD; Thomas A. Slater, MBBS;  
Aaron Koshy, MBBS; Sam Straw, MBChB; John Gierula, PhD; Maria Paton, MSc; Judith Lowry, MSc;  
Robert Sapsford, MBChB, MD; Klaus K. Witte, MBChB, MD; Mark T. Kearney, MBChB, MD; Richard M. Cubbon , MBChB, PhD
BACKGROUND: Hospitalization is a common adverse event in people with heart failure and reduced ejection fraction, yet is often 
not primarily due to decompensated heart failure (HF). We investigated the long-term prognosis following infection-related 
hospitalization.
METHODS: We conducted a prospective observational cohort study of 711 people with heart failure and reduced ejection 
fraction recruited from 4 specialist HF clinics in the United Kingdom. All hospitalization episodes (n=1568) were recorded and 
categorized as primarily due to decompensated HF, other cardiovascular disease, infection-related, or other noncardiovascular 
disease. Survival was determined after the first hospitalization.
RESULTS: During 2900 patient-years of follow-up, there were a total of 14 686 hospital days. At least one hospitalization occurred 
in 467 people (66%); 25% of first hospitalizations were primarily due to infection and these were not associated with typical signs 
including tachycardia and pyrexia. Compared with other categories of hospitalization, infection-related was associated with older age, 
lower serum albumin, higher blood neutrophil counts, and greater prevalence of chronic obstructive pulmonary disease at recruitment. 
Median survival after first infection-related hospitalization was 18.6 months, comparable to that after first decompensated HF 
hospitalization, even after age-sex adjustment. The burden of all-cause rehospitalization was comparable irrespective of the category 
of first hospitalization, but infection more commonly caused re-hospitalization after index infection hospitalization.
CONCLUSIONS: Infection is a common driver of hospitalization in heart failure and reduced ejection fraction and often presents 
without classical signs. It is associated with high mortality rates, comparable to decompensated HF, and a major burden of 
rehospitalization caused by recurrent episodes of infection.
Key Words: heart failure ◼ hospitalization ◼ infections ◼ mortality ◼ survival
The improving survival rates of people with heart failure with reduced ejection fraction (HFrEF) have been accompanied by notable changes in the mode 
of death, with noncardiovascular causes becoming 
increasingly important.1–3 We, and others, have shown 
that sepsis accounts for a substantial proportion of this 
noncardiovascular mortality,4,5 and that sepsis death has 
a distinct risk factor profile from other modes of death.4 
It is also established that infection is a common primary 
cause of hospitalization in people with heart failure,5,6 yet 
the prognostic implications of this remain uncertain. In 
particular, we remain unclear about long-term survival 
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and the burden of rehospitalization after an index infec-
tion-related hospitalization, versus other common causes. 
We set out to address this uncertainty by following up a 
cohort of people with stable HFrEF attending 4 specialist 
heart failure clinics.
METHODS
The datasets generated and/or analyzed during the current 
study are not publicly available due to inclusion of potentially 
identifying postal codes but are available from the correspond-
ing author on reasonable request.
As described in our earlier publications,7–9 we conducted 
a prospective observational cohort study with the predefined 
aim of studying outcomes and defining prognostic markers 
in patients with HFrEF. The cohort consists of 3 discretely 
recruited subgroups and this analysis is restricted to the most 
recently recruited group of 711 people, as detailed hospital-
ization data are available. Inclusion in the study required the 
presence of stable signs and symptoms of CHF for at least 
3 months, age ≥18 years, and left ventricular ejection fraction 
≤45% on transthoracic echocardiography. Between February 
2012 and December 2014, all patients meeting these cri-
teria and attending specialist cardiology clinics (secondary 
and tertiary referral) in 4 UK hospitals were approached, and 
711 patients provided written informed consent. Participants 
received routine contemporary evidence-based care, guided by 
the supervising clinical team, with no study intervention; they 
were then observed until censorship or death, as described 
below. The Leeds West Research Ethics Committee gave ethi-
cal approval, all patients provided written informed consent to 
participate, and the investigation conformed to the principles 
outlined in the Declaration of Helsinki.
Patient baseline characteristics including demograph-
ics, past medical history, functional capacity, electrocardiog-
raphy, laboratory blood tests, cardiac imaging, and treatment 
were collected at study recruitment. Vital signs and laboratory 
blood tests relating to the index hospitalization were collected 
at the point of presentation. Two-dimensional echocardiog-
raphy was performed according to the American Society of 
Echocardiography recommendations. Resting heart rate was 
measured using 12-lead ECGs. Prescribed doses of loop 
diuretics, angiotensin-converting enzyme inhibitors, angioten-
sin receptor blockers, and β-blockers were collected at study 
recruitment. Total daily doses of β-blocker, angiotensin-convert-
ing enzyme inhibitors (or angiotensin receptor blocker if used 
instead of angiotensin-converting enzyme inhibitors), and loop 
diuretic were expressed relative to the maximal licensed dose 
of bisoprolol, ramipril, and furosemide, respectively, as previ-
ously published.8 Receipt of cardiac resynchronization therapy 
(CRT) and implantable cardioverter-defibrillator implantation 
was assessed during the 6-month period after recruitment.
Assessment of Outcomes
All patients were registered with the UK Office of Population 
Censuses and Surveys, which provided details of time of death, 
with a final censorship date of February 18, 2019. Hospitalization 
data were collected from institutional clinical event databases 
detailing all admissions in recruiting centres. All nonelective hospi-
tal admissions experienced before death or study censorship were 
included and characterized by 2 investigators according to their 
time from study recruitment, duration, and primary cause within 4 
following major categories: (1) heart failure (HF) hospitalization; (2) 
other cardiovascular hospitalization (eg, arrhythmia or acute coro-
nary syndrome, without decompensated HF); (3) infection-related 
hospitalization; (4) other noncardiovascular hospitalization (noncar-
diovascular cause excluding infection-related). HF hospitalization 
was defined as new onset or worsening of signs and symptoms 
of heart failure with evidence of fluid overload requiring at least 
24 hours hospitalization and the use of intravenous diuretics, as 
Nonstandard Abbreviations and Acronyms
COPD chronic obstructive pulmonary disease
CRT cardiac resynchronization therapy
HF heart failure
HFrEF  heart failure with reduced ejection 
fraction
WHAT IS NEW?
• Hospitalization is common in people with heart failure 
and reduced ejection fraction and infection accounts 
for approximately one quarter of these events.
• Baseline characteristics, such as comorbid chronic 
obstructive pulmonary disease and not having an 
implantable cardioverter-defibrillator/cardiac resyn-
chronization therapy device, predict risk of infection 
hospitalization.
• Median survival after infection hospitalization is 18.6 
months, which is comparable to that after decom-
pensated heart failure hospitalization, and signifi-
cantly worse than after other types of hospitalization.
• Infection is more commonly responsible for re-hos-
pitalization after index infection hospitalization ver-
sus other causes of index hospitalization.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Clinicians should have a high index of suspicion for 
infection when hospitalizing people with heart failure 
and reduced ejection fraction since classical mark-
ers like heart rate and body temperature are similar 
irrespective of the ultimate cause of admission. 
• The poor in-hospital survival of people with infec-
tion suggests intensive monitoring and treatment 
may be necessary, but additional research is 
needed to prove this. 
• Infection hospitalization is more common in some 
people, such as those with chronic obstructive pul-
monary disease, and re-hospitalization after a first 
infection hospital admission is more likely to be due 
to recurrent infection, highlighting the importance 
of developing effective primary and secondary pre-
vention strategies.
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we have previously published.9 Infection-related hospitalization was 
defined as infection being the primary reason for hospitalization 
with documented source (or suspected source), accompanied by 
deteriorating symptoms, signs (eg, pyrexia, tachycardia, hypoten-
sion, tachypnea, confusion), and laboratory indices (eg, elevated 
inflammatory markers, with microbiological, serological, and/or 
imaging evidence) resulting in treatment with antimicrobial therapy, 
as we have previously published.4 Sources included the following: 
respiratory tract, biliary/gastrointestinal, urinary tract (including 
cystitis, pyelonephritis etc), soft-tissue infections (eg, cellulitis, gan-
grene, necrotizing fasciitis), and unknown.
Statistics
All statistical analyses were performed using IBM SPSS statis-
tics version 21 (IBM Corporation, Armonk, NY). Continuous data 
are presented as mean (SEM) or median (interquartile range) for 
normal and non-normally distributed variables, respectively, and 
categorical data are shown as number (percentage). Groups were 
compared using Student t-tests or ANOVA for normally distributed 
continuous data, Mann-Whitney U-tests or Kruskal-Wallis H-tests 
for non-normally distributed continuous data, and Pearson χ2 
tests for categorical data. Kaplan-Meier curves were used to plot 
survival and compared with log-rank tests; age-sex adjusted sur-
vival analyses used Cox-regression analysis. Rehospitalized time 
was expressed as a percentage of time in follow-up before death 
or censorship to account for differing survival between groups 
and was compared using ANOVA with post hoc Bonferroni cor-
rection. To further illustrate patterns of rehospitalized time due 
to infection and other classifications, patients were subdivided 
according to duration of follow-up. All tests were 2-sided, and 
statistical significance was defined as P<0.05.
RESULTS
Baseline characteristics of the entire cohort of 711 peo-
ple are presented in Table 1. During a mean follow-up 
period of 48.6 months, 467 (66%) were hospitalized at 
least once, and 25% of first hospitalizations were primar-
ily attributable to infection, 14% to decompensated HF, 
25% to other cardiovascular causes, and 37% to other 
noncardiovascular causes (Figure 1A); when assessing 
first and recurrent hospitalizations, similar contributions 
were observed (Figure I in the Data Supplement). The 
source of infection during first hospitalization was most 
commonly the respiratory tract (50%), followed by soft-
tissue (18%) and the urinary tract (17%; Figure 1B). The 
median duration of infection-related hospitalization was 
twice as long as noninfection related hospitalization (8 
[5–16] versus 4 [2–9] days; P=0.002); for reference, the 
mean duration was 13.8 (95% CI, 10.8–16.8) days ver-
sus 7.8 (95% CI, 6.7–8.9) days.
Compared with people with a first hospitalization due 
to other causes, those hospitalized due to infection were 
older, had lower serum albumin, higher blood neutro-
phil counts, were more likely to have chronic obstructive 
pulmonary disease (COPD), and less likely to have an 
implantable cardioverter-defibrillator/CRT device at study 
recruitment (Table 1). In a multivariate logistic regres-
sion analysis including these variables, only COPD and 
implantable cardioverter-defibrillator/CRT device were 
significantly associated with risk of infection hospitalization 
(Table I in the Data Supplement). At the point of hospital 
admission, blood pressure and oxygen saturations (SpO
2) 
were lower, while respiratory rate and blood leukocyte 
counts were higher in people with infection-related hos-
pitalization (Table 1). Core body temperature was higher 
in the infection-related group and heart rate was no differ-
ent. Data describing people with infection-related hospi-
talization versus those within the 3 other major categories 
of hospitalization (Table 2) indicate that the prevalence 
of COPD is higher in the infection-related group, while 
baseline diuretic requirements are greater in those going 
on to decompensated HF hospitalization. At the point of 
the index hospitalization, the infection-related group had 
a lower diastolic blood pressure and SpO2 than the other 
groups, along with higher blood leukocyte counts.
Survival
Infection-related hospitalization was associated with an 
age-sex adjusted 3.6-fold (95% CI, 1.6–8.1) greater 
risk of death during the admission versus hospitalization 
for any other reason. This remained the case when the 
binary logistic regression model also included baseline 
characteristics that differed between groups (odds ratio, 
3.5 [95% CI, 1.4–8.4]; P=0.005; Table II in the Data Sup-
plement). Importantly, these odds ratios do not account 
for the longer duration of infection hospitalizations.
Kaplan-Meier analysis confirms worse long-term sur-
vival in those with infection (P=0.001), illustrating early 
divergence in survival after discharge from hospital, most 
pronounced during the first 3 months, after which the 
groups remain broadly parallel (Figure 2A). In an age-
sex adjusted Cox regression analysis, infection was 
associated with 1.4-fold greater risk of death ([95% CI, 
1.1–1.8]; P=0.012). When age, sex, and baseline char-
acteristics that differed between groups were added to 
the model, the hazard ratio reduced slightly and lost-sta-
tistical significance (hazard ratio, 1.3 [95% CI, 1.0–1.7]; 
P=0.085; Table III in the Data Supplement).
To explore the survival of patients with infection-
related hospitalization versus the other 3 major sub-
types of hospitalization, we plotted Kaplan-Meier 
survival curves (Figure 2B), which reveal that infection 
and decompensated HF hospitalizations are associ-
ated with significantly worse survival than other car-
diovascular and noncardiovascular hospitalizations 
(P<0.001). The median survival of people with infec-
tion-related hospitalization was 18.6 months (95% 
CI, 9.0–28.3), which is similar to the 20.6 months 
(95% CI, 9.4–31.8) of people with decompensated 
HF hospitalization (P=0.98). This statistically similar 
adverse prognosis of infection and decompensated 
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HF hospitalization groups persisted in Cox regression 
analysis (Table IV in the Data Supplement) including 
age, sex, and the baseline characteristics differing 
between the 4 major subtypes of hospitalization in 
Table 2.
Rehospitalization
Next, we assessed re-hospitalization attributable to 
infection after an index hospitalization with infection ver-
sus other major categories, using data from 1101 re-
hospitalization episodes. This showed that the burden 
Table 1. Characteristics at Recruitment and Onset of First Hospitalization for Infection-Related vs Noninfection 
Hospitalization
Total Cohort (n=711)
No Hospitalization 
(n=244)
Infection-Related 
Hospitalization (n=115)
Noninfection 
Hospitalization (n=352)
P Value (Infection-
Related Versus 
Noninfection)
Age, y 71.6 (13.0) 68.3 (12.6) 75.3 (10.1) 72.6 (13.6) 0.028
Heart rate, bpm 76.0 (17.0) 77.0 (18.2) 77.4 (16.3) 74.9 (16.5) 0.30
Systolic BP, mm Hg 125.2 (21.4) 124.6 (21.7) 124.0 (19.3) 125.9 (21.7) 0.50
Diastolic BP, mm Hg 71.0 (10.6) 72.6 (10.6) 71.1 (11.3) 70.0 (10.3) 0.44
QRS interval, ms 121.8 (30.9) 125.3 (30.4) 117.6 (30.5) 120.8 (31.2) 0.33
Hemoglobin, g/dL 13.3 (1.8) 13.8 (1.7) 13.1 (2.1) 13.0 (1.8) 0.78
WCC, ×109/L 7.5 (2.1) 7.4 (1.9) 7.8 (2.3) 7.4 (2.2) 0.19
Lymphocytes, ×109/L 1.6 (0.8) 1.6 (0.6) 1.5 (0.7) 1.6 (0.9) 0.17
Neutrophils, ×109/L 5.0 (1.7) 4.9 (1.6) 5.3 (1.9) 4.9 (1.7) 0.03
Platelets, ×109/L 236.4 (75.2) 240.1 (75.4) 229.7 (72.7) 236.1 (76.0) 0.43
Sodium, mmol/L 139.6 (3.2) 139.9 (2.8) 139.2 (3.6) 139.5 (3.4) 0.40
eGFR, mL/kg per min 61.8 (21.7) 67.1 (19.5) 58.9 (24.0) 59.2 (21.6) 0.91
Albumin, g/L 42.4 (3.6) 43.3 (3.7) 41.3 (3.3) 42.1 (3.6) 0.041
Vitamin D, nmol/L 33 (20–54) 37 (20–57) 32 (20–52) 30 (18–53) 0.43
LVEF (%) 31.8 (9.9) 31.2 (9.8) 32.2 (9.9) 32.1 (9.9) 0.93
Ramipril dose, mg/d 4.9 (3.5) 5.1 (3.5) 4.5 (3.5) 4.8 (3.6) 0.41
Bisoprolol dose, mg/d 4.3 (3.4) 4.6 (3.4) 3.7 (3.1) 4.3 (3.4) 0.10
Furosemide dose, mg/d 48.8 (47.5) 39.3 (44.0) 55.1 (44.8) 53.4 (49.8) 0.74
MRA prescription, n (%) 245 (35) 82 (34) 34 (30) 129 (37) 0.12
ICD/CRT, n (%) 153 (22) 64 (26) 9 (8) 80 (23) <0.001
Male sex, n (%) 516 (73) 179 (73) 87 (76) 250 (71) 0.34
Diabetes mellitus, n (%) 224 (32) 61 (25) 47 (41) 116 (33) 0.12
COPD, n (%) 116 (16) 27 (11) 39 (34) 50 (14) <0.001
Ischemic etiology, n (%) 379 (53) 110 (45) 68 (59) 201 (57) 0.70
NYHA class 0.63
 I, n (%) 107 (15) 50 (21) 11 (9) 46 (13)  
 II, n (%) 408 (57) 144 (59) 68 (59) 196 (56)  
 III, n (%) 192 (27) 48 (20) 35 (30) 109 (31)  
 IV, n (%) 4 (1) 2 (1) 1 (1) 1 (0)  
Presenting observations (n=467)     
 Heart rate, bpm 80.0 (21.9) N/A 80.6 (21.3) 79.8 (22.2) 0.75
 Systolic BP, mm Hg 124.6 (28.0) N/A 117.7 (26.0) 126.8 (28.3) 0.011
 Diastolic BP, mm Hg 70.8 (16.3) N/A 65.4 (16.3) 72.4 (15.9) 0.001
 Respiratory rate, per min 20.1 (5.0) N/A 22.4 (6.0) 19.4 (4.4) <0.001
 Oxygen saturations, % 96.0 (4.4) N/A 93.8 (6.1) 96.6 (3.4) <0.001
 Temperature, °C 36.4 (36.0–36.8) N/A 36.6 (36.0–37.4) 36.3 (36.0–36.7) 0.003
 WCC, ×109/L 10.4 (5.5) N/A 13.8 (6.6) 9.1 (4.5) <0.001
 Neutrophils, ×109/L 8.0 (5.0) N/A 11.7 (6.4) 6.7 (3.6) <0.001
BP indicates blood pressure; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; ICD, 
implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; N/A, not applicable; NYHA, New York heart 
association; QRS, Q, R and S waves on the electrocardiogram; and WCC, white cell count.
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of infection re-hospitalization was greater after index 
infection-related hospitalization versus index decom-
pensated HF, other cardiovascular, and other noncar-
diovascular admissions (P=0.004 by ANOVA; Figure 3). 
This observation persisted in analyses stratified by dura-
tion of follow-up (Figure II in the Data Supplement). 
Hence, infection accounted for the majority of rehospi-
talized time after index infection-related admission and 
this endured even over the long term, suggesting these 
patients form a distinct group at risk of recurrent infec-
tion-related events.
DISCUSSION
Our detailed analysis of hospitalization in people with 
HFrEF suggests that infection is a common cause of 
these events, accounting for a quarter of first hospital-
ization events. Baseline study characteristics identified 
people more likely to experience future hospitalization 
due to infection, versus other major causes, and at the 
point of hospitalization, the infection-related hospitaliza-
tion group had greater physiological disturbance. Impor-
tantly, people admitted due to infection were as likely to 
die in the short- and long-term as people admitted with 
decompensated HF, a group already recognized to have 
poor prognosis. Furthermore, recurrent infection was a 
major driver of rehospitalization, particularly after index 
infection hospitalization. Cumulatively, these data sug-
gest that infection is a common, serious, and distinct 
cause of hospitalization in people with HFrEF, which 
may benefit from improved prevention, early identifica-
tion, and intensive management.
Infection and Adverse Events in HF Cohorts
Only a small number of other studies have explored the 
relationship between infection and outcomes in people 
with HF. Alon et al6 found that 38% of people with HF 
had at least one sepsis hospitalization, with the source 
of infection being broadly similar to our data; they also 
found increased 30-day mortality after infection-associ-
ated versus other hospitalizations. Ueda et al5 similarly 
reported a high short-term mortality rate in people with 
HF after hospitalization with infection. Our data advance 
the literature by showing for the first time that short- and 
long-term survival after infection-related hospitalization 
is as poor as after admission with decompensated HF, a 
widely acknowledged high-risk event.10,11 Moreover, we 
show that after an infection hospitalization, the predomi-
nant cause of rehospitalization is infection.
Predictors of Future Infection-Related Adverse 
Events
Our data indicate that some patient characteristics at 
study recruitment are associated with future infection 
versus other subtypes of hospitalization, including: 
older age, lower serum albumin, higher blood neu-
trophil count, the presence of COPD, and not having 
an implantable cardioverter-defibrillator/CRT. While 
these are unlikely to allow precise identification of 
people who will go on to experience infection-related 
hospitalization, they do highlight at-risk groups and 
may also point to mechanisms of infection suscepti-
bility. In particular, COPD was at least twice as com-
mon in people going on to be admitted with infection 
versus any other type of hospitalization and is a 
well-recognized substrate for respiratory tract infec-
tion.12 Higher baseline neutrophil counts at baseline 
recruitment are unlikely to reflect active infection, 
given their modest elevation and the time lag to first 
hospitalization, but has been repeatedly linked with 
old age.13–15 This, together with lower serum albumin, 
could also reflect frailty, a syndrome associated with 
susceptibility to infection and impaired physiological 
reserve.16 Importantly, our prior work has shown that 
COPD and advancing age are the 2 strongest predic-
tors of sepsis death in people with HFrEF, highlight-
ing the importance of these factors in predicting both 
infection-related hospitalization and death.4 The much 
lower provision of implantable cardioverter-defibrilla-
tor/CRT devices to people that subsequently expe-
rience an infection hospitalization is also notable in 
the context of their similar LV ejection fraction and 
A B
Figure 1. Classification of first 
hospitalizations.
Classification of (A) the principal cause 
of hospitalization and (B) the source of 
infection. CV indicates cardiovascular.
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prevalence of ischemic etiology. This factor indepen-
dently predicted infection hospitalization, possibly 
suggesting that clinicians recognized the differing 
prognosis of these people using factors we have not 
measured and used this information when making 
treatment recommendations.
Table 2. Characteristics at Recruitment and Onset of First Hospitalization for Infection-Related Versus Other Subtypes of 
Hospitalization
Heart Failure 
Hospitalization (n=64)
Other CV Hospitalization 
(n=116)
Other Non-CV 
Hospitalization (n=172)
Infection-Related 
Hospitalization (n=115) P Value
Age, y 74.4 (11.2) 72.3 (13.7) 72.3 (14.3) 75.3 (10.1) 0.17
Heart rate, bpm 76.2 (15.0) 73.4 (15.5) 75.5 (17.4) 77.4 (16.3) 0.58
Systolic BP, mm Hg 122.5 (22.2) 127.4 (22.5) 126.0 (21.1) 124.0 (19.3) 0.59
Diastolic BP, mm Hg 68.2 (10.3) 70.5 (10.7) 70.2 (10.1) 71.1 (11.3) 0.57
QRS interval, ms 125.0 (31.9) 122.0 (31.5) 118.4 (30.7) 117.6 (30.5) 0.35
Hemoglobin, g/dL 12.8 (1.8) 13.2 (1.9) 13.0 (1.7) 13.1 (2.1) 0.54
WCC, ×109/L 7.2 (2.0) 7.5 (2.2) 7.5 (2.3) 7.8 (2.3) 0.42
Lymphocytes, ×109/L 1.4 (0.6) 1.6 (0.7) 1.7 (1.0) 1.5 (0.7) 0.12
Neutrophils, ×109/L 4.7 (1.7) 4.9 (1.7) 4.9 (1.7) 5.3 (1.9) 0.15
Platelets, ×109/L 243.7 (94.7) 222.2 (67.4) 242.6 (72.8) 229.7 (72.7) 0.09
Sodium, mmol/L 139.1 (4.5) 139.7 (3.1) 139.6 (3.1) 139.2 (3.6) 0.55
eGFR, mL/kg per min 56.3 (21.4) 57.6 (21.3) 61.3 (21.8) 58.9 (24.0) 0.36
Albumin, g/L 41.4 (4.4) 42.6 (2.8)† 42.1 (3.8) 41.3 (3.3)† 0.031
Vitamin D, nmol/L 31.0 (18.2–46.0) 35.0 (25.0–56.3) 30.0 (19.0–48.0) 30.0 (18.0–53.0) 0.17
LVEF (%) 31.9 (9.5) 31.9 (10.2) 32.3 (9.9) 32.2 (9.9) 0.98
Ramipril dose, mg/d 4.4 (3.3) 4.9 (3.6) 4.9 (3.7) 4.5 (3.5) 0.59
Bisoprolol dose, mg/d 4.0 (3.6) 4.4 (3.4) 4.3 (3.5) 3.7 (3.1) 0.32
Furosemide dose, mg/d 71.9 (44.2)§∥ 48.8 (50.5)§ 49.5 (49.9)∥ 55.1 (44.8) 0.009
MRA prescription, n (%) 24 (38) 42 (36) 63 (37) 34 (30) 0.58
ICD/CRT, n (%) 16 (25)* 30 (26)† 34 (20)‡ 9 (8)*†‡ 0.002
Male sex, n (%) 46 (72) 85 (73) 119 (69) 87 (76) 0.68
Diabetes mellitus, n (%) 29 (45)∥ 43 (37) 44 (26)∥‡ 47 (41)‡ 0.009
COPD, n (%) 11 (17) 15 (13)† 24 (14)‡ 39 (34)†‡ <0.001
Ischemic etiology, n (%) 36 (56) 73 (63) 92 (54) 68 (59) 0.44
NYHA class 0.27
 I, n (%) 5 (8) 18 (15) 23 (13) 11 (10)  
 II, n (%) 33 (52) 59 (51) 104 (61) 68 (59)  
 III, n (%) 25 (39) 39 (34) 45 (26) 35 (30)  
 IV, n (%) 1 (1) 0 (0) 0 (0) 1 (1)  
Presenting observations
 Heart rate, bpm 85.1 (24.9) 79.5 (24.4) 78.1 (19.0) 80.6 (21.3) 0.36
 Systolic BP, mm Hg 125.0 (32.5) 127.3 (24.5) 127.1 (29.7) 117.7 (26.0) 0.09
 Diastolic BP, mm Hg 73.8 (18.6)* 72.3 (14.6)† 72.0 (16.0)‡ 65.4 (16.3)*†‡ 0.008
 Respiratory rate, per min 21.3 (5.5)∥ 19.2 (4.5)† 18.9 (3.6)∥‡ 22.4 (6.0)†‡ <0.001
 Oxygen saturations, % 95.8 (3.7) 96.9 (2.3)† 96.7 (4.0)‡ 93.8 (6.1)†‡ <0.001
 Temperature, °C 36.4 (36.0–36.7) 36.3 (36.0–36.6) 36.3 (36.0–36.8) 36.6 (36.0–37.4) 0.24
 WCC, ×109/L 8.3 (2.6)* 8.9 (3.5)† 9.6 (5.4)‡ 13.8 (6.6)*†‡ <0.001
 Neutrophils, ×109/L 6.1 (2.3)* 6.5 (3.3)† 7.1 (4.0)‡ 11.7 (6.4)*†‡ <0.001
BP indicates blood pressure; COPD, chronic obstructive pulmonary disease; CRT, cardiac resynchronization therapy; CV, cardiovascular; eGFR, estimated glomerular 
filtration rate; ICD, implantable cardioverter-defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NYHA, New York heart 
association; QRS, Q, R and S waves on the electrocardiogram; and WCC, white cell count.
*Infection versus heart failure Bonferroni corrected P<0.05.
†Infection versus other cardiovascular Bonferroni corrected P<0.05.
‡Infection versus other noncardiovascular Bonferroni corrected P<0.05.
§Heart failure versus other cardiovascular Bonferroni corrected P<0.05.
∥Heart failure versus other noncardiovascular Bonferroni corrected P<0.05.
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Presenting Features of Infection-Related 
Hospitalization
At the point of hospital admission, our data show that infec-
tion is associated with hypotension, particularly reflected in 
the diastolic blood pressure, hypoxemia, and increased cir-
culating leukocyte counts, potentially signaling physiologi-
cal compromise. Surprisingly, heart rate was similar in all 
groups, irrespective of the cause of admission, suggesting 
that tachycardia is a less reliable marker of acute infec-
tion in HFrEF, which could reflect the use of β-blockers. 
Moreover, a point measure of body temperature did not 
reliably discriminate people with and without infection, 
possibly reflecting its transient nature, but also potentially 
suggesting altered acute inflammatory responses. These 
data suggest that infection may be more challenging to 
diagnose in people with HFrEF, emphasizing the need for 
a high index of suspicion at the point of hospitalization.
Limitations
We recognize that hospitalizations are complex and mul-
tifactorial, meaning that classification according to the 
primary cause neglects other contributory factors. It is 
important to note that comorbid heart failure will aggra-
vate the outcome of a primary infection, and infection 
is a recognized precipitant of decompensated HF.17–20 
Therefore, while our data show that people presenting 
primarily with infection are different from those hospi-
talized primarily for other reasons, identification of high-
risk patients, early detection and optimal management 
of infection should be an important goal in HFrEF care. 
Importantly, our study may also underestimate rates 
of hospitalization as we utilized institutional data from 
recruiting centres, rather than nationally collected data.
Clinical Implications
Our findings have implications for patients, clinicians, and 
healthcare systems and also pose important questions 
that require further research. First, the substantial con-
tribution to index hospitalizations suggests that greater 
efforts are required to prevent infection. For example, the 
uptake of influenza vaccination remains suboptimal in 
many healthcare systems, including in the United King-
dom,21 and there may be scope to improve the efficacy 
of vaccination in disease states associated with impaired 
immune responses.22 Second, while people with HFrEF 
presenting acutely with infection had somewhat dif-
ferent physiological parameters to other patients, their 
presentation often lacked typical features of infection 
(eg, tachycardia), suggesting a high index of suspicion 
is required, along with better diagnostic tests.23 Unfor-
tunately, we lack data to state whether this somewhat 
atypical presentation resulted in delayed use of antimi-
crobials, which is known to be associated with adverse 
outcomes. Moreover, the very high in hospital mortal-
ity rate associated with infection poses the question of 
whether more intensive monitoring, supportive care, and 
postdischarge care could improve survival and long-term 
functioning.24 Finally, recurrent infection hospitalization 
A B
Figure 2. Survival from moment of first hospitalization.
Kaplan-Meier curves illustrating survival from the point of first hospitalization, comparing (A) infection-related hospitalization vs noninfection 
hospitalization and (B) infection-related hospitalization vs other major classifications of hospitalization. Numbers at risk are presented below 
the x-axis.
Figure 3. Contribution of infection to the burden of re-
hospitalized time.
Stacked bar chart illustrating the percentage of follow-up time in 
hospital after discharge from the index admission due to infection 
and other major categories of re-hospitalization. The burden 
of infection re-hospitalization is greater after index infection 
hospitalization than other categories (P=0.004 by ANOVA).
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was common, highlighting a need for secondary preven-
tion strategies.
Conclusions
Infection is a major contributor to hospitalization in 
people with HFrEF, yet may be difficult to identify and 
often presents without classical signs. It is associated 
with short- and long-term mortality rates as high as after 
hospitalization with decompensated HF and a sustained 
larger burden of recurrent infection-related hospitaliza-
tion than after other types of index hospitalization. This 
suggests that new approaches to prevent, identify, and 
treat infection could substantially improve the outcomes 
of people with HFrEF.
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